Medical treatment after peripheral bypass surgery over the past decade

European Journal of Vascular and Endovascular Surgery

Volumn 41, Issue 6, 2011, Pages 805-813

  Van Hattum, E S ^a   Tangelder, M J D ^a   Huis in 't Veld, M A ^a   Lawson, J A ^b   Algra, A ^a,c   Moll, F L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b AMSTELLAND HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antihypertensive drugs; Antithrombotics; Infrainguinal bypass surgery; Lipid lowering drugs; Peripheral arterial disease

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBASALATE CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHENPROCOUMON;

AGED; ARTICLE; BYPASS SURGERY; CLINICAL PRACTICE; FEMALE; FOLLOW UP; GRAFT OCCLUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VASCULAR SURGERY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NETHERLANDS; PERIPHERAL ARTERIAL DISEASE; POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR GRAFTING;

EID: 79955953135     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2010.12.016     Document Type: Article

References (36)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR, on behalf of the TASC II Working Group. Intersociety consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007;33(Suppl. 1):S1-75.
2. Pereira CE, Albers M, Romiti M, Brochado-Neto FC, Braganaa Pereira CA. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg 2006;44:510-7.
3. Tangelder MJ, Lawson JA, Algra A, Eikelboom B. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J Vasc Surg 1999;30:701-9. (Pubitemid 29487563)
4. The Dutch BOA Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch bypass oral anticoagulants or aspirin study): a randomised trial. Lancet 2000;355:346-51.
5. Lawson JA. Antitrombotica bij perifere bypass-chirurgie in Nederland. Ned Tijdschr Geneeskd 1992;136:998 [abstract].
6. Van Hattum ES. Praktijk: De beste nabehandeling. Trombose voorkomen na een perifere bypass. Medisch Contact 2006;61:120-1.
7. Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Rother J, et al. Three-year follow-up and event rates in the international reduction of atherothrombosis for continued health registry. Eur Heart J 2009;30:2318-26.
8. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
9. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
10. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
11. Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006;47:1182-7.
12. Feringa HH, Karagiannis SE, van Waning VH, Elhendy A, Boersma E, Schouten O, et al. The effect of intensified lipidlowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg 2007;45:936-43. (Pubitemid 46661787)
13. Dorffler-Melly J, Koopman MM, Adam DJ, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2003;CD000535.
14. Dorffler-Melly J, Buller HR, Koopman MM, Prins MH. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2003;CD000536.
15. Kretschmer G, Wenzl E, Piza F, Polterauer P, Ehringer H, Minar E, et al. The influence of anticoagulant treatment on the probability of function in femoropopliteal vein bypass surgery: analysis of a clinical series (1970-1985) and interim evaluation of a controlled clinical trial. Surgery 1987;102:453-9.
16. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998;28:446-57. (Pubitemid 28421716)
17. Watson HR, Skene AM, Belcher G. Graft material and results of platelet inhibitor trials in peripheral arterial reconstructions: reappraisal of results from a meta-analysis. Br J Clin Pharmacol 2000;49:479-83. (Pubitemid 30229452)
18. Klinkert P, Post PN, Breslau PJ, van Bockel JH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg 2004;27:357-62. (Pubitemid 38386920)
19. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002;35:413-21. (Pubitemid 44718584)
20. Anand S, Yusuf S, Xie C, The Warfarin Antiplatelet Vascular Evaluation Trial investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357:217-27. (Pubitemid 47080386)
21. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:815S-43S.
22. De Buyzere ML, Clement DL. Management of hypertension in peripheral arterial disease. Prog Cardiovasc Dis 2008;50:238-63. (Pubitemid 350301981)
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72. (Pubitemid 37430158)
24. Mehler PS, Coll JR, Estacio R, Estacio R, Esler A, Schrier RW, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107:753-6. (Pubitemid 36222605)
25. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906. (Pubitemid 41265663)
26. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769-76.
27. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-421.
28. Bismuth J, Klitfod L, Sillesen H. The lack of cardiovascular risk factor management in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg 2001;21:143-6. (Pubitemid 32243907)
29. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24. (Pubitemid 33015522)
30. Gasse C, Jacobsen J, Larsen AC, Schmidt EB, Johannesen NL, Videbaek J, et al. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction. Eur J Vasc Endovasc Surg 2008;35:51-8. (Pubitemid 350245449)
31. Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, van Domburg RT, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol 2008;51:1588-96. (Pubitemid 351509419)
32. Duffield RG, Lewis B, Miller NE, Jamieson CW, Brunt JN, Colchester AC. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet 1983;2:639-42. (Pubitemid 13003482)
33. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hådell K, Johansson J, et al. The effect of probucol on femoral atherosclerosis: the Probucol quantitative regression swedish trial (PQRST). Am J Cardiol 1994;74:875-83. (Pubitemid 24340308)
34. Kretschmer G, Wenzl E, Schemper M, Polterauer P, Ehringer H, Marçosi L, et al. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. Lancet 1988;1:797-9.
35. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapyeI: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
36. Sillesen H. Who should treat patients with peripheral arterial disease - the vascular specialist. Eur J Vasc Endovasc Surg 2002;24:1-3. (Pubitemid 41079379)